PMID- 38483082
OWN - NLM
STAT- MEDLINE
DCOM- 20240315
LR  - 20240322
IS  - 1651-2057 (Electronic)
IS  - 0001-5555 (Print)
IS  - 0001-5555 (Linking)
VI  - 104
DP  - 2024 Mar 14
TI  - Discontinuation of Fumaric Acid Esters is Affected by Depressive Symptomatology: 
      A Retrospective Analysis.
PG  - adv12326
LID - 10.2340/actadv.v104.12326 [doi]
LID - 12326
AB  - Fumaric acid esters (FAEs) remain a widespread therapy option for 
      moderate-to-severe psoriasis. However, drug survival of FAEs is limited by 
      adverse events (AEs) or inadequate treatment response. Depressive disturbances 
      are highly prevalent in psoriasis patients and are hypothesized to be associated 
      with the reporting of AEs and therapy discontinuation. This study's aim was to 
      analyze whether psoriasis patients with comorbid depressive symptomatology are 
      more likely to discontinue treatment with FAEs due to AEs and/or inadequate 
      treatment response. Data were retrospectively extracted from the records of 
      patients starting therapy with FAEs in the Department of Dermatology, University 
      Hospital Essen, Germany between 2017 and 2022, covering the first 52 weeks of 
      treatment. Psoriasis severity and depressive symptomatology, as well as AEs and 
      therapy discontinuation, were analyzed. Psoriasis patients (N = 95, 47.37% 
      female) with depressive symptomatology (42.11%) were more likely to discontinue 
      therapy due to patient-reported AEs, while the total number of reported AEs was 
      not associated with depression. The results support the hypothesis that among 
      psoriasis patients with depressive symptoms, the associated introspection and 
      somatization may result in increased sensitivity for AEs and thus in quicker 
      therapy discontinuation. In these patients, the occurrence of nocebo effects 
      should be minimized, e.g. by special communication techniques.
FAU - Krefting, Frederik
AU  - Krefting F
AD  - Department of Dermatology, Venereology and Allergology, University Hospital 
      Essen, University of Duisburg-Essen, Essen, Germany. 
      Frederik.krefting@uk-essen.de.
FAU - Holsken, Stefanie
AU  - Holsken S
AD  - Institute of Medical Psychology and Behavioral Immunobiology, University Hospital 
      Essen, University of Duisburg-Essen, Essen, Germany.
FAU - Schedlowski, Manfred
AU  - Schedlowski M
AD  - Institute of Medical Psychology and Behavioral Immunobiology, University Hospital 
      Essen, University of Duisburg-Essen, Essen, Germany; Department of Clinical 
      Neuroscience, Osher Center for Integrative Medicine, Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Sondermann, Wiebke
AU  - Sondermann W
AD  - Department of Dermatology, Venereology and Allergology, University Hospital 
      Essen, University of Duisburg-Essen, Essen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20240314
PL  - Sweden
TA  - Acta Derm Venereol
JT  - Acta dermato-venereologica
JID - 0370310
RN  - 0 (Fumarates)
RN  - 0 (Dermatologic Agents)
SB  - IM
MH  - Humans
MH  - Female
MH  - Male
MH  - Fumarates/adverse effects
MH  - Retrospective Studies
MH  - *Dermatologic Agents/adverse effects
MH  - *Psoriasis/diagnosis/drug therapy/chemically induced
MH  - Germany/epidemiology
MH  - Treatment Outcome
PMC - PMC10953706
COIS- FK Krefting has received travel support and/or consulting fees from Almirall and 
      Novartis outside the submitted work. WS reports grants from Almirall with 
      reference to the submitted work and/or travel support and/or personal fees and/or 
      speaker honoraria from medi GmbH Bayreuth, Abbvie, Amgen, Bristol-Myers Squibb, 
      Celgene, GSK, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi 
      Genzyme, and UCB outside the submitted work. MS reports speaker honoraria from 
      Almirall, Lilly, Bristol-Myers Squibb, Janssen, Berlin Chemie, Abbvie, and Mylan 
      outside the submitted work. SH declares no conflicts of interest.
EDAT- 2024/03/14 12:44
MHDA- 2024/03/15 06:43
PMCR- 2024/03/14
CRDT- 2024/03/14 08:24
PHST- 2023/04/13 00:00 [received]
PHST- 2024/02/22 00:00 [accepted]
PHST- 2024/03/15 06:43 [medline]
PHST- 2024/03/14 12:44 [pubmed]
PHST- 2024/03/14 08:24 [entrez]
PHST- 2024/03/14 00:00 [pmc-release]
AID - ActaDV-104-12326 [pii]
AID - 10.2340/actadv.v104.12326 [doi]
PST - epublish
SO  - Acta Derm Venereol. 2024 Mar 14;104:adv12326. doi: 10.2340/actadv.v104.12326.